{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-002389","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2025-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.605762+00:00","generated_at":"2026-05-28T01:26:06.202558+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Mangoceuticals subsidiary creates Series A Preferred Stock granting CEO 51% voting control","bullets":["Series A Preferred Stock of M&P subsidiary gives holders 51% of total vote on all shareholder matters.","100 shares designated; expected to be issued to CEO Jacob Cohen under his employment agreement.","M&P cannot amend charter or issue more shares without 66-2/3% approval of Series A holders.","Designation filed Jan 9, 2025, effective same date; filed with Texas SOS on Jan 15."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-002389","json":"https://secwatch.observer/filing/0001493152-25-002389.json","markdown":"https://secwatch.observer/filing/0001493152-25-002389.md","text":"https://secwatch.observer/filing/0001493152-25-002389.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315225002389/0001493152-25-002389-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315225002389/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:26:06.202558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}